The medical license number accurately identifies the prescribing physician in a large pharmacy claims database

Medical Care

Volumn 45, Issue 9, 2007, Pages 907-910

  Brookhart, M Alan ^a   Avorn, Jerry ^a   Polinksi, Jennifer M ^a   Brown, Theresa V ^a   Mogun, Helen ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Data quality; Pharmacoepidemiology; Validation study

Indexed keywords

BONE DENSITY CONSERVATION AGENT;

ARTICLE; CLASSIFICATION; COHORT ANALYSIS; DRUG USE; FACTUAL DATABASE; FEE; HEALTH INSURANCE; HUMAN; INSURANCE; LICENSING; MEDICAL SOCIETY; MEDICARE; OSTEOPOROSIS; PHYSICIAN; PRESCRIPTION; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

AMERICAN MEDICAL ASSOCIATION; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DRUG UTILIZATION REVIEW; HUMANS; INSURANCE CLAIM REPORTING; INSURANCE, PHARMACEUTICAL SERVICES; LICENSURE, MEDICAL; MEDICARE PART B; OSTEOPOROSIS; PHYSICIANS; PRESCRIPTION FEES; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 34548065444     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3180616c67     Document Type: Article

References (11)

1. Schneeweiss S, Glynn RJ, Avorn J, et al. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005;58:98-102.
2. Solomon DH, Schneeweiss S, Glynn RJ, et al. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important. Am J Med. 2003;115:715-720.
3. Solomon DH, Brookhart MA, Polinski J, et al. Osteoporosis action: design of the healthy bones project trial. Contemp Clin Trials. 2005;26:78-94.
4. Solomon DH, Polinski JM, Truppo C, et al. Access to bone mineral density testing in patients at risk for osteoporosis. Osteoporos Int. 2006;17:1749-1754.
5. Morrato EH, Staffa JA. Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data. Pharmacoepidemiol Drug Saf. 2007;16:104-112.
6. Bambauer KZ, Adams AS, Zhang F, et al. Physician alerts to increase antidepressant adherence: fax or fiction. Arch Intern Med. 2006;166:498-504.
7. Brookhart MA, Wang PS, Solomon DH, et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17:268-275.
8. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341.
9. Heller DA, Ahern FM, Kozak M. Changes in rates of beta-blocker use between 1994 and 1997 among elderly survivors of acute myocardial infarction. Am Heart J. 2000;140:663-671.
10. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414-2419.
11. Baldwin LM, Adamache W, Klabunde CN, et al. Linking physician characteristics and Medicare claims data: issues in data availability, quality, and measurement. Med Care. 2002;40(8 suppl):IV-82-IV-95.